PrEP drug highly effective at reducing risk of HIV, study says

NHS England’s national director for specialised commissioning, John Stewart, added: “Not only did the trial directly prevent many cases of HIV, help normalise the use of PrEP, remove stigma and pave the way for a routinely commissioned clinically and cost effective PrEP service, but it also made a very real contribution towards our goal of ending new cases of HIV by 2030.”